EBMT 2026 | Beyond CD19: the potential of tandem CD19/CD22 CAR T-cells in high-risk B-ALL
In this video, Antonio Pérez-Martínez, MD, PhD, Autonomous University of Madrid, Madrid, Spain, briefly discusses the potential of tandem CD19/CD22 CAR T-cells for high-risk B-cell acute lymphoblastic leukemia (B-ALL). He highlights that while anti-CD19 CAR T-cell therapy is effective for a proportion of patients, more than 50% relapse in the long term, and targeting both CD19 and CD22 may offer another chance at remission. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We already know that CD19 CAR T-cell is very useful for most of the refractory patients. However, in the long term, more than 50% of the patients, they relapse. When they relapse after CAR-T19, the options to take another remission are very, very, very little. So because of that, we propose to multi-target the B-cell leukemia in this refractory patient to the CAR-T19 in order to give another chance to induce another remission, and in the case, consolidate with another transplant or another consolidation strategy...
We already know that CD19 CAR T-cell is very useful for most of the refractory patients. However, in the long term, more than 50% of the patients, they relapse. When they relapse after CAR-T19, the options to take another remission are very, very, very little. So because of that, we propose to multi-target the B-cell leukemia in this refractory patient to the CAR-T19 in order to give another chance to induce another remission, and in the case, consolidate with another transplant or another consolidation strategy. This is what we presented on the first day at the EBMT meeting, and we presented our experience with 13 patients that had already received previously a CAR T19, they relapsed, and we were able to rescue most of them. 70% of them responded to the treatment, and with a median survival of more than two years, they are alive. So we are very happy because of that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
